Last reviewed · How we verify
prednisone plus cyclophosphamide
prednisone plus cyclophosphamide is a Corticosteroid plus alkylating agent combination Small molecule drug developed by Guangdong Provincial People's Hospital. It is currently FDA-approved for Severe autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis), Hematologic malignancies and lymphomas, Severe refractory autoimmune conditions.
Prednisone suppresses immune and inflammatory responses while cyclophosphamide acts as an alkylating agent to kill rapidly dividing cells, together providing immunosuppression and cytotoxic effects.
Prednisone and cyclophosphamide are used in the treatment of various lymphomas, including lymphoblastic lymphoma, peripheral T-cell lymphoma, and B-cell non-Hodgkin lymphoma. Cyclophosphamide is a small molecule DNA inhibitor that works by inhibiting DNA, according to its mechanism of action.
At a glance
| Generic name | prednisone plus cyclophosphamide |
|---|---|
| Sponsor | Guangdong Provincial People's Hospital |
| Drug class | Corticosteroid plus alkylating agent combination |
| Modality | Small molecule |
| Therapeutic area | Immunology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Prednisone is a corticosteroid that inhibits inflammatory cytokine production and immune cell activation. Cyclophosphamide is an alkylating chemotherapy agent that cross-links DNA and causes cell death, particularly affecting rapidly dividing lymphocytes. This combination leverages both immunosuppressive and cytotoxic mechanisms to treat autoimmune and hematologic conditions.
Approved indications
- Severe autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis)
- Hematologic malignancies and lymphomas
- Severe refractory autoimmune conditions
Common side effects
- Infection
- Myelosuppression
- Hemorrhagic cystitis
- Nausea and vomiting
- Immunosuppression-related complications
- Corticosteroid-related side effects (hyperglycemia, osteoporosis)
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prednisone plus cyclophosphamide CI brief — competitive landscape report
- prednisone plus cyclophosphamide updates RSS · CI watch RSS
- Guangdong Provincial People's Hospital portfolio CI
Frequently asked questions about prednisone plus cyclophosphamide
What is prednisone plus cyclophosphamide?
How does prednisone plus cyclophosphamide work?
What is prednisone plus cyclophosphamide used for?
Who makes prednisone plus cyclophosphamide?
What drug class is prednisone plus cyclophosphamide in?
What development phase is prednisone plus cyclophosphamide in?
What are the side effects of prednisone plus cyclophosphamide?
Related
- Drug class: All Corticosteroid plus alkylating agent combination drugs
- Manufacturer: Guangdong Provincial People's Hospital — full pipeline
- Therapeutic area: All drugs in Immunology / Oncology
- Indication: Drugs for Severe autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis)
- Indication: Drugs for Hematologic malignancies and lymphomas
- Indication: Drugs for Severe refractory autoimmune conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing